Preparing the published article.
Company Profile: MicroPort MedBot (Shanghai MicroPort Medbot Group)
A public-source profile of MicroPort MedBot covering surgical platforms, device-specific regulatory evidence, dated international activity and hospital procurement questions.
Company identity and surgical focus
MicroPort MedBot develops robotic systems for surgery. Its official history traces the laparoscopic robotics project to 2014, incorporation in China to 2015 and a 2021 rename to Shanghai MicroPort Medbot (Group) Co., Ltd. The business covers several surgical specialties, so the MedBot brand should be distinguished from a particular robot, subsidiary or contracting entity. The current contact page identifies the Shanghai group company and a separate orthopedic business in Suzhou. Company history; Corporate contacts.
Toumai and the wider product portfolio
Toumai is a surgeon-controlled laparoscopic platform comprising a surgeon console, patient cart and imaging unit. The portfolio also includes DFVision for three-dimensional laparoscopic imaging, SkyWalker for orthopedic surgery and the Mona Lisa system for robot-assisted transperineal prostate biopsy. These products serve different procedural workflows and cannot be treated as interchangeable configurations of one robot. Official product solutions.
The same portfolio page marks Automated Needle Targeting and the trans-bronchial robot as lacking NMPA approval on that page. A product's presence in the portfolio therefore does not establish current commercial availability. Obtain an updated model and market schedule, including the instruments and software supplied with each system. Product status descriptions.
Device-specific regulatory boundaries
The FDA letter dated July 7, 2022 for K213873 names the SkyWalker Total Knee System and MicroPort NaviBot International LLC. This is a device-specific 510(k) clearance; it is not clearance for Toumai or every orthopedic application in the broader company portfolio. International buyers should match the quoted model, software, instruments and intended use to the destination country's current documentation. FDA K213873 decision and device summary.
Dated commercial and hospital examples
In a release posted February 13, 2026, with a February 11 dateline, MedBot reported more than 200 Toumai commercial orders and close to 130 commercially installed systems. Those figures are manufacturer-reported and distinguish contracted demand from completed installation; they do not describe a verified installation count today. February 2026 commercial update.
An October 9, 2025 announcement named Gemelli Hospital in Italy and AZ Delta in Belgium as Toumai users and described Rajavithi Hospital in Thailand as a training center. These dated examples support international activity, while their procedure totals and commercial status remain statements from the supplier. A prospective hospital should request a reference appropriate to its specialty and jurisdiction. Named hospital and training examples.
Clinical workflow, training and implementation
For Toumai, the clinician works through the console while the patient-side system and imaging equipment support the procedure. The product page describes applications across urology, general surgery, gynecology and thoracic surgery; local labeling determines the permitted scope for a particular installation. MedBot also publishes a professional training program. The practical implementation brief should cover operating-room layout, instrument preparation, sterilization, surgeon and team training, support during initial cases and service escalation. Toumai workflow; Professional training.
Questions for a hospital procurement team
Which legal entity supplies the exact system, and who provides service in the destination country?
Which local indications, instruments and software versions are included in the offer?
What room preparation, imaging connections, sterilization capacity and staffing are required?
What training, supervised introduction and competency assessment are included?
How are instrument life, recurring consumables, maintenance, spare parts and downtime handled?
If remote operation is proposed, what additional approvals, connectivity requirements, clinical responsibilities and recovery arrangements apply?
These questions should be resolved for the proposed configuration before comparing total ownership cost or implementation schedules. Discuss a system proposal.
Official commercial contact
The English contact page provides a company inquiry form and the general customer email MB_customer@microport.com. It identifies the Shanghai address at 1601 Zhangdong Road and the domestic telephone 400-900-3155. An international request should state the destination country, hospital, department, proposed procedures and installation timetable, and ask for the responsible local commercial and service organization. MedBot contact details.
Evidence limits and buyer resources
Manufacturer product pages and announcements describe the portfolio and reported activity; they are not independent proof of better clinical outcomes. Regulatory evidence here is limited to the specifically named FDA device. Portfolio descriptions, overseas orders and hospital examples do not establish worldwide availability, equivalent indications or a guaranteed result for patients. Pricing and supply commitments require a model-specific offer. Device-specific evidence; Commercial-source context.
Continue with Medical and Rehabilitation Robotics, Write a Robotics Buyer Brief or Robotics RFQ.